Glaucoma, a leading cause of irreversible blindness worldwide, is primarily managed by regulating elevated intraocular pressure. However, conventional methods rely heavily on episodic clinic visits and patient-dependent drug regimens that often fail to capture the dynamic fluctuations in IOP. Dr. Zhu’s research addresses this critical gap by creating a wearable smart contact lens that not only monitors IOP continuously in vivo but also autonomously delivers medication when pathological pressure thresholds are detected, ensuring timely and personalized treatment.

The smart contact lens leverages a fully polymer-based architecture that is both biocompatible and flexible, facilitating prolonged ocular wear without compromising patient comfort. Embedded within the lens are advanced microfluidic channels and biosensors capable of sampling aqueous humor parameters with high sensitivity. The sensor data is processed in real time using machine learning algorithms engineered to discern subtle pressure variations indicative of glaucomatous progression, triggering a closed-loop response to administer therapeutics through on-demand drug release reservoirs integrated seamlessly into the lens matrix.

This multi-functional platform embodies an unprecedented synthesis of biomedical engineering, materials science, and artificial intelligence. The continuous monitoring capability offers a more comprehensive and dynamic understanding of IOP trends, transcending the limitations of standard tonometry. Furthermore, the closed-loop feedback system mitigates risks associated with over- or under-medication by regulating dosage based on precise physiological parameters, thereby optimizing therapeutic efficacy while minimizing side effects.

Preclinical evaluations have demonstrated the lens’s robustness in animal models, confirming its ability to retain optical clarity, mechanical resilience, and drug release precision under physiological conditions. Importantly, the all-polymer design circumvents issues commonly encountered with rigid electronic components, including mechanical mismatch and biofouling, thereby enhancing long-term functionality and patient adherence. These promising outcomes pave the way for translational efforts aiming to validate safety and performance in human clinical trials.

Dr. Zhu emphasizes the transformative nature of the technology, noting that “our design fundamentally shifts the paradigm from reactive to proactive ocular care by embedding intelligence directly at the disease interface.” This innovation aligns with a broader trend in biomedical research striving to develop theranostic devices—systems that unify diagnosis and therapy—in order to provide targeted, automated interventions that adapt in real time to individual patient needs.

The publication marks a seminal moment for the Terasaki Institute, underscoring its commitment to developing sophisticated, patient-centric biomedical solutions that bridge the divide between laboratory innovation and clinical utility. Stewart Han, President of the Institute, highlights that “this achievement exemplifies how interdisciplinary collaboration and translational research can generate breakthroughs that directly impact patient quality of life.”

Beyond glaucoma management, the smart contact lens platform holds potential versatility for diagnosing and treating a spectrum of ocular diseases characterized by fluctuating biomarkers, including diabetic retinopathy and uveitis. The underlying design principles could be adapted for multiplexed sensing and multi-drug release strategies, heralding a new era of personalized ophthalmic therapeutics that integrate seamlessly with daily life.

This innovation also dovetails with global efforts to harness wearable technologies for continuous health monitoring, bringing a new dimension to ambulatory diagnostics and responsive drug delivery systems. By embedding AI intelligence in a non-invasive, user-friendly device, it offers a practical solution to the increasing burden of chronic eye diseases and the need for remote, precision healthcare.

Looking ahead, the researchers aim to refine the device’s sensing specificity, enhance the durability of the drug reservoirs, and optimize the integrated AI algorithms through large-scale clinical validation. Collaboration with ophthalmologists, materials scientists, and regulatory agencies will be pivotal to ensuring the technology meets stringent safety standards and achieves wide clinical adoption.

As ocular diseases continue to impose significant healthcare challenges globally, innovations such as Dr. Zhu’s smart contact lens represent a beacon of hope. By transforming traditional disease management into a closed-loop, intelligent process, this technology promises to improve therapeutic outcomes, reduce healthcare costs, and most importantly, preserve vision and enhance the quality of life for millions of patients worldwide.

The Terasaki Institute’s breakthrough underscores the power of convergence research in crafting next-generation biomedical devices that are not merely passive tools but active participants in patient health management. It signals a paradigm shift in ophthalmology and wearable health technologies, marrying the precision of engineering with the complexities of human physiology in a compact, accessible form factor.

As this research transitions toward clinical translation, it is poised to inspire further innovations at the intersection of smart materials, biosensing, and AI-driven healthcare, guiding the future of personalized medicine towards a new frontier where treatment pathways are adaptive, automated, and intimately tuned to the nuances of individual patient behavior and disease trajectories.

Subject of Research: Not applicable

Article Title: Real-time intraocular pressure monitoring and responsive drug release in preclinical models by an all-polymer smart contact lens

News Publication Date: 8-Apr-2026

Web References: DOI: 10.1126/scitranslmed.ads9541

Image Credits: Terasaki Institute

Keywords

Medical technology; Biosensors; Ophthalmology; Wearable devices; Biomedical engineering; Drug delivery

At the core of XPANCEO’s innovation lies a sophisticated dual-layer nano-stripe pattern integrated into the contact lens surface, subdivided into four discrete sections arranged side-by-side. These sections consist of two ultra-thin optical gratings stacked with a minute microscopic gap. As the wearer’s eye moves and the angle of view changes relative to the camera, the gratings interact to produce shifting moiré interference patterns—dynamic optical illusions created by the superposition of repetitive structures. The relative movement and deformation of these patterns enable a passive, yet highly sensitive, mechanism to decode the precise orientation and motion of the eye. This novel biocompatible assembly, encapsulated within a thin silicone elastomer compatible with standard contact lens manufacturing, measures a mere 2.5 by 2.5 millimeters, underscoring its unobtrusive nature.

Traditional eye-tracking systems predominantly rely on active illumination, particularly infrared light, to stimulate reflective features on the corneal and crystalline lens surfaces. Conventional cameras then capture glint positions and pupil shapes that sophisticated computer vision algorithms process to compute gaze direction and eye orientation. This process, involving cyclic near-infrared illumination and imaging, demands considerable power consumption and frequently suffers degradation in environments with abundant ambient light. These limitations have historically confined high-precision eye tracking to specialized devices with constrained usability in everyday scenarios.

In stark contrast, the novel moiré-based contact lens technology circumvents the challenges of active illumination by functioning purely on optical geometry. The absence of infrared emitters simplifies hardware requirements immensely and allows seamless operation in bright environments where infrared signals often become overwhelmed by ambient lighting. This energy-efficient and camera-compatible system capitalizes on the ubiquitous presence of imaging technology embedded not only in personal devices like laptops and smartphones but also in sophisticated settings such as automotive dashboards and helmet-mounted displays. The universal compatibility promises extensive deployment possibilities without the need for bespoke tracking hardware.

Dr. Valentyn Volkov, XPANCEO’s Founder and Chief Technology Officer, emphasizes that this breakthrough introduces an unprecedented marriage between optical physics and wearable technology. By exploiting moiré interferometry principles, the team has crafted a method where eye orientation can be measured with impressive precision — about 0.3 degrees — without the complexity, energy demand, or discomfort associated with previous technologies. This capability unlocks new frontiers for contact lens platforms, particularly in contexts where users are frequently engaging with camera-equipped interfaces.

The clinical implications of such high-fidelity eye movement detection are particularly captivating. Eye-tracking has emerged as a critical biomarker in diagnosing and monitoring neurological conditions with subtle manifestations in ocular motility, such as Parkinson’s and Alzheimer’s diseases. High-resolution, yet minimally invasive, tracking solutions capable of operating in everyday environments could facilitate earlier detection protocols and improve patient monitoring without relying on clinical equipment. This contact lens approach, by seamlessly integrating into the user’s daily life, holds promise for transforming neurodegenerative disease diagnostics via unobtrusive biometrics.

Beyond healthcare applications, the robustness of the moiré pattern tracking system makes it well-suited for deployment in demanding environments where monitoring operator alertness and cognitive state is vital. In fields such as aviation, automotive safety, and industrial labor, continuous tracking of micro-fixations and saccadic velocities can offer deeper insight than conventional fatigue assessments. The technology enables real-time detection of central nervous system fatigue, cognitive decline, or intoxication states, thereby ensuring that operators maintain optimal functionality and safety while performing critical tasks.

This contact lens technology elegantly sidesteps the energy and computational overhead challenges found in current active eye-tracking systems. By relying exclusively on passive optical interference effects and existing camera hardware, it dramatically lowers system complexity and power requirements. The encapsulated nano-stripe gratings create an optical signature that can be decoded efficiently by conventional image sensors using standard algorithms, facilitating integration with the vast ecosystem of consumer and professional devices already equipped with cameras.

Material considerations also receive significant attention. The encapsulation’s biocompatible silicone elastomer ensures wearer comfort and compatibility with current contact lens manufacturing. Maintaining such compatibility is crucial for scalability and market adoption, as manufacturing processes do not require major alterations. This seamless production integration paves the way for widespread availability without prohibitive costs, positioning the innovation as a practical solution rather than a niche prototype.

From a technical perspective, the dynamic interplay between the two nano-stripe gratings separated by a microscopically small gap is fundamental to moiré pattern evolution as viewed by the camera. The interference pattern shifts predictably with angular changes of the eye, essentially translating rotational motion into detectable optical signals. This sophisticated optical geometry leverages principles akin to mechanical pop-up books, where layered elements move relative to each other to create complex visual effects. Translating these movements into quantitative rotational data constitutes a notable advancement in wearable optical sensing.

The implications extend toward smart device ecosystems, where such passive eye-tracking lenses could foster new human-device interaction modalities. For example, laptops and smartphones could passively determine user gaze patterns and attentiveness without additional hardware investment or battery burden. Similarly, augmented and virtual reality headsets equipped with embedded cameras could enhance gaze-dependent rendering and interface control using solely the contact lens markers. This opens avenues not only for improved usability but also for energy savings and device miniaturization.

In conclusion, XPANCEO’s moiré-pattern eye-tracking contact lens embodies a cutting-edge convergence of photonic engineering, wearable technology, and biomedical sensing. Its passive, camera-readable design redefines the potential for high-accuracy gaze tracking, eliminating the bottlenecks of power consumption, environmental sensitivity, and hardware complexity that limit current systems. By opening new clinical, industrial, and consumer applications, this breakthrough stands poised to herald a new era in eye-tracking technology that is more accessible, reliable, and multifunctional.

Subject of Research: High-precision passive eye-tracking via moiré-patterned smart contact lenses
Article Title: Contact Lens with Moiré Patterns for High-Precision Eye Tracking
News Publication Date: 9-Jan-2026
Web References:

• https://www.xpanceo.com
• https://advanced.onlinelibrary.wiley.com/doi/full/10.1002/adfm.202522757
  References:
• Parkinson’s disease and eye-tracking biomarkers: https://pubmed.ncbi.nlm.nih.gov/40309816/
• Alzheimer’s disease and ocular motor function: https://pmc.ncbi.nlm.nih.gov/articles/PMC12750316/
• Fatigue and cognitive impairment detection via eye movements: https://pubmed.ncbi.nlm.nih.gov/33825234/ & https://pubmed.ncbi.nlm.nih.gov/20377146/
  Image Credits: XPANCEO

Keywords

Electrooculography, Eye Tracking, Moiré Pattern, Smart Contact Lens, Passive Optical Sensing, Neurodegenerative Biomarkers, Wearable Technology